EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study

Duc Binh Phan, Hugo Jourdain, Miguel Angel Descalzo-Gallego, Alicia González-Quesada, Mahmoud Zureik, Raquel Rivera-Díaz, Antonio Sahuquillo-Torralba, Mark Lunt, Ignacio Garcia-Doval iD, Emilie Sbidian iD, Richard B Warren iD, Zenas Z N Yiu iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljae454 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Duc Binh Phan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR), Manchester Biomedical Resear…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Psoriasis, Adalimumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Manchester, British Association of Dermatologists Biologic Register Ltd, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The lack of evidence from routine clinical settings has limited the widespread adoption of adalimumab biosimilars for the treatment of psoriasis.

Objectives

To compare the drug survival and safety of adalimumab biosimilars with Humira® in psoriasis.

Methods

We conducted a prevalent new-user cohort study using data from the French National Health Data System (SNDS), the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) and the Spanish Registry of Systemic Therapy in Psoriasis (BIOBADADERM). Adalimumab-naïve patients initiating adalimumab biosimilars (new users) were compared with Humira new users. Patients switching from Humira to biosimilars (switchers) were compared with those who continued Humira treatment. Patients were matched 1 : 1 based on previous adalimumab exposure time to create equal-sized cohorts of biosimilar and Humira users. Co-primary outcomes included drug discontinuation and serious adverse events (SAEs). Hazard ratios (HRs) were calculated using Cox proportional hazard models. Meta-analyses using random-effect models were performed to combine results from the three databases.

Results

In total, 7387 biosimilar new users and 3654 switchers were matched and compared with Humira users. No differences in all-cause discontinuation were found between biosimilar and Humira new users [HR 0.99, 95% confidence interval (CI) 0.94–1.04]. Switching from Humira to biosimilars was associated with a higher discontinuation rate than remaining on Humira (HR 1.35, 95% CI 1.19–1.52). Similar results were observed for discontinuation due to ineffectiveness or adverse events. Risks of SAEs were similar between biosimilar new users and Humira new users [incidence rate ratio (IRR) 0.91, 95% CI 0.80–1.05] or between switchers and continuous Humira users (IRR 0.92, 95% CI 0.83–1.01).

Conclusions

Adalimumab biosimilars can be considered viable alternatives to Humira for new patients, with comparable effectiveness and safety. However, owing to the higher likelihood of discontinuation, patients who switch from Humira to biosimilars may require closer monitoring and support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsPsoriasisAdalimumabHumansFemaleMaleMiddle AgedAdultDrug SubstitutionTreatment OutcomeCohort StudiesAgedSafety-Based Drug Withdrawals

Substanzen

Biosimilar PharmaceuticalsAdalimumab

Autor:innen und Institutionen

  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research (NIHR), Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Acad…
  • EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France.
  • Research Unit, Fundacion Piel Sana AEDV, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain.

ORCID-Profile: Ignacio Garcia-Doval, Emilie Sbidian, Richard B Warren, Zenas Z N Yiu

Förderung

  • University of Manchester
  • British Association of Dermatologists Biologic Register Ltd
  • AbbVie
  • Almirall
  • Bristol Myers Squibb
  • Boehringer Ingelheim
  • Eli Lilly
  • Janssen Cilag

Zitieren

APA

Phan, D. B., Jourdain, H., Descalzo-Gallego, M. A., González-Quesada, A., Zureik, M., Rivera-Díaz, R., Sahuquillo-Torralba, A., Lunt, M., Garcia-Doval, I., Sbidian, E., Warren, R. B., & Yiu, Z. Z. N. (2025). Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae454

Vancouver

Phan DB, Jourdain H, Descalzo-Gallego MA, González-Quesada A, Zureik M, Rivera-Díaz R, et al. Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae454

BibTeX
@article{Phan2025,
  author = {Phan, Duc Binh and Jourdain, Hugo and Descalzo-Gallego, Miguel Angel and González-Quesada, Alicia and Zureik, Mahmoud and Rivera-Díaz, Raquel and Sahuquillo-Torralba, Antonio and Lunt, Mark and Garcia-Doval, Ignacio and Sbidian, Emilie and Warren, Richard B and Yiu, Zenas Z N},
  title = {Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljae454}
}
Kostenlos starten →